HomeCompareQFREF vs MRK

QFREF vs MRK: Dividend Comparison 2026

QFREF yields 158.73% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 QFREF wins by $33.38M in total portfolio value
10 years
QFREF
QFREF
● Live price
158.73%
Share price
$1.26
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.43M
Annual income
$14,929,974.02
Full QFREF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — QFREF vs MRK

📍 QFREF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodQFREFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, QFREF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
QFREF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

QFREF
Annual income on $10K today (after 15% tax)
$13,492.06/yr
After 10yr DRIP, annual income (after tax)
$12,690,477.92/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, QFREF beats the other by $12,681,881.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of QFREF + MRK for your $10,000?

QFREF: 50%MRK: 50%
100% MRK50/50100% QFREF
Portfolio after 10yr
$16.75M
Annual income
$7,470,043.90/yr
Blended yield
44.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

QFREF
No analyst data
Altman Z
2.5
Piotroski
5/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

QFREF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricQFREFMRK
Forward yield158.73%2.81%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$33.43M$57.7K
Annual income after 10y$14,929,974.02$10,113.78
Total dividends collected$31.06M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: QFREF vs MRK ($10,000, DRIP)

YearQFREF PortfolioQFREF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$26,573$15,873.02$11,213$373.04+$15.4KQFREF
2$67,853$39,419.99$12,667$512.06+$55.2KQFREF
3$166,675$94,072.29$14,439$708.14+$152.2KQFREF
4$394,305$215,962.78$16,640$988.16+$377.7KQFREF
5$899,388$477,481.77$19,432$1,394.07+$880.0KQFREF
6$1,980,205$1,017,859.40$23,057$1,992.90+$1.96MQFREF
7$4,213,254$2,094,435.11$27,889$2,894.79+$4.19MQFREF
8$8,672,949$4,164,766.74$34,518$4,286.29+$8.64MQFREF
9$17,292,333$8,012,278.11$43,912$6,494.35+$17.25MQFREF
10$33,432,771$14,929,974.02$57,714$10,113.78+$33.38MQFREF

QFREF vs MRK: Complete Analysis 2026

QFREFStock

Q-Free ASA supplies intelligent transportation system products and solutions worldwide. It offers tolling products, such as dedicated short-range communication on-board units, roadside transceivers/antennas, handheld transceivers/digital tachographs, and automated license plate recognition (ALPR) cameras/imaging systems. The company also provides Intrada ALPR, an automatic license plate recognition and vehicle analytics solution; Intrada Insight, an image processing and review solution; and Intrada Synergy Server, an image processing solution for video-based passages, such as tolling and parking/access control. In addition, it offers traffic management products, including Urban hardware, such as ATC controllers and cabinets; urban software comprising central and local traffic control software systems, as well as ramp meter, analytics, adaptive, and connected vehicle software enhancements; interurban software, such as Statewide ATMS, a statewide freeway traffic management software system, as well as software enhancements for work zone and event management; and infomobility hardware products, including high- and low-speed weigh-in-motion systems, as well as traffic counting and classification products for vehicles, bicycles, and pedestrians. The company also provides maintenance services. Q-Free ASA was founded in 1984 and is headquartered in Trondheim, Norway.

Full QFREF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this QFREF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

QFREF vs SCHDQFREF vs JEPIQFREF vs OQFREF vs KOQFREF vs MAINQFREF vs JNJQFREF vs ABBVQFREF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.